Oxfam

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.

 

Vaccines


Approved or authorized vaccines
 
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
 
The U.S.…


The state of the hunt: 

Novavax became the biggest recipient of CEPI funds for Covid-19 this week, with a new $384 million award for its recombinant protein vaccine candidate. CureVac’s mRNA vaccine candidate induced high levels of virus-neutralizing titers at a low dose in preclinical studies. Gilead announced voluntary royalty-free licenses for remdesivir with five generic drug manufacturers, and more may be in the works.
 

 

Vaccines

Our Covid-19…

Oxfam released research yesterday saying that Abbott, Johnson & Johnson, Merck and Pfizer hide their profits in overseas havens, “dodging” annual tax payments worth nearly $2.3 billion in the United States, $1.4 billion in other advanced economies and $112 million in developing countries.

Oxfam said pharmaceutical companies’ exploitation of tax loopholes prevent governments from providing services that are essential to reducing poverty and investing in medical R&D.

Mentions:

Oxfam published a briefing document last week alleging that western governments are prioritizing pharmaceutical companies’ interests by delaying action on the UN High-Level Panel on Access to Medicines (HLP), which reported its findings a year ago.

The UN Secretary-General asked the HLP to address the conflict between intellectual property protections for pharmaceutical companies contained within trade agreements and governments’ commitment to human rights goals, particularly the UN’s…

Mentions: